Caricamento...
Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files
Targeted radiopharmaceutical conjugates intended for therapeutic use often are made of three key components, a decaying radionuclide, a chemical chelator/linker, and a targeted molecular entity. The National Cancer Institute (NCI) Experimental Therapeutics Program has accepted four radiopharmaceutic...
Salvato in:
| Pubblicato in: | Front Oncol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6611355/ https://ncbi.nlm.nih.gov/pubmed/31316916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00573 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|